Moderna's Cancer Treatment: A Ray of Hope?

Moderna's stock price jumped on promising early results for its mRNA-4359 cancer treatment when combined with Merck’s Keytruda, showing tumor shrinkage in melanoma patients, especially those with the PD-L1 marker. Despite the positive news and a boost to the stock price amid a broader market rebound, investors remain cautiously optimistic due to Moderna's volatile stock history and the inherent risks in the biotech sector.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.